Articles

Incidence of Colorectal Cancer Rising in Young Adults
Cancer Awareness, Colorectal Cancer
Web Exclusives
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years.
Read More
FDA Granted Second Approval for Epkinly to Treat Patients With Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates, Lymphoma, Bispecific Antibodies
Web Exclusives
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
Read More
Pembrolizumab With Chemotherapy for Some Endometrial Carcinomas Gets Green Light
FDA Approvals, News & Updates
Web Exclusives
FDA officials approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma efficacy of this treatment was evaluated in KEYNOTE-868/NRG-GY018.
Read More
Quick Quiz: Prostate Cancer Edition
Quick Quiz: Prostate Cancer Edition
Prostate Cancer
Quick Quizzes
According to the National Cancer Institute, prostate cancer is the most common cancer in US men and the second highest cause of cancer death in this patient population. In fact, an estimated 299,010 new cases will be diagnosed in 2024 and approximately 12.9% of men will receive this diagnosis in their lifetime. Thus, a significant portion of your patients and their loved ones will be affected by the disease. As the nation spotlights men’s health awareness this June, test your knowledge on this prevalent disease.
Read More
Addressing Cancer Health Disparities: The No One Left Alone Initiative
By Rohan Nathwani; Arva Patel; Warner Kornberg; Asutosh Gor, MD; Sashi Naidu, MD; Viral Rabara, MD; Niyati Nathwani, MD; Kashyap Patel, MD
Health Disparities
Web Exclusives
Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. Place of birth is more strongly associated with life expectancy than race or genetics.
Read More
Navigating the Complex Landscape of Oral Cancer Medication
Oral Oncolytics
Web Exclusives
Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes.
Read More
Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice
Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice
In this supplement, expert faculty offer detailed perspectives based on their experience to summarize, examine, and analyze the emerging results from studies of anticancer biosimilars and provide recommendations to improve the adoption of and access to biosimilar products.
Read More
Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On November 8, 2023, the FDA approved fruquintinib (Fruzaqla; Takeda Pharmaceuticals), an inhibitor of VEGFR-1, -2, and -3, for the treatment of metastatic colorectal cancer (mCRC) in adults who received previous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The FDA granted fruquintinib priority review for this indication.
Read More
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
By William King
ESMO, Lung Cancer
December 2023, Vol 14, No 6
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.
Read More
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On October 27, 2023, the FDA approved toripalimab-tpzi (Loqtorzi; Coherus BioSciences), a PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine chemotherapy, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma, and as a single agent for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that progressed during or after treatment with a platinum-containing chemotherapy.
Read More

Page 6 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?